SSB 3170: SSB 3170

What it does

This bill relates to Code chapter 144E, the right to try Act. Under current law, an “eligible patient” under the Code chapter is, in part, a person who has a terminal illness. Under the bill, an “eligible patient” also includes, in part, a person who has a life-threatening or severely debilitating illness. Under current law, the Code chapter applies to an “investigational drug, biological product, or device”, meaning a drug, biological product, or device that has successfully completed phase I of a United States food and drug administration (FDA)-approved clinical trial but has not yet been approved for general use by the FDA and that remains under investigation in an FDA-approved clinical trial.

Senate subcommittee · named February 8, 2024

• Sen. Jeff Taylor (R) · jeff.taylor@legis.iowa.gov
• Sen. Kevin Alons (R) · kevin.alons@legis.iowa.gov
• Sen. Zach Wahls (D) · zach.wahls@legis.iowa.gov

Lobbying · 3 for, 0 against

For: Americans For Prosperity; Goldwater Institute; Heartland Impact

In plain words

1. February 8, 2024Filed in the Senate and sent to the Technology committee
2. February 8, 2024Senate subcommittee named: Taylor, J., Alons and Wahls
3. February 13, 2024Subcommittee recommended passing it
4. February 13, 2024Approved by the Senate committee, and given a new number: SF 2323